Combining two dietary compounds found in green tea and carrots reversed cognitive deficits, lowered the accumulation of toxic amyloid beta, and reduced brain inflammation and oxidative damage in a mouse model of Alzheimer’s disease, a study reports. The study, “Combined treatment with the phenolics (−)-epigallocatechin-3-gallate and ferulic…
Neurotrope Bioscience announced that dosing of patients has started in its Phase 2 clinical trial to further evaluate Bryostatin-1, the company’s investigational candidate for the treatment of moderate to severe Alzheimer’s disease. “Completion of enrollment in our confirmatory Phase 2 trial is an important step toward understanding the transformative…
People with sleep apnea show increased accumulation of tau protein aggregates — a hallmark of Alzheimer’s disease — in brain regions linked to memory and spatial navigation, a study finds. The results will be presented during the 71st Annual Meeting of the American Academy of Neurology, May 4–10 in…
Because a disproportionate number of Alzheimer’s disease patients and caregivers are women, the Alzheimer’s Association and The Women’s Alzheimer’s Movement (WAM) are leading a global movement to do something about it. Announced March 8 on International Women’s Day, efforts include a South by Southwest (SXSW) Conference…
Manipulating astrocytes — a type of cell in the brain — to deliver a protein that favors the survival of neurons can rescue cognitive function, including memory, in a mouse model of Alzheimer’s disease, a study reports. The study, “Conditional BDNF delivery from astrocytes rescues memory deficits, spine density…
Abnormal levels of amyloid-beta and tau protein — two hallmarks of Alzheimer’s disease — were detected in the cerebrospinal fluid of older individuals without dementia who were hospitalized for hip fractures, a study shows. These findings suggest that alterations that can cause diminished balance in older people may underly both increased…
Hispanic-American patients with Alzheimer’s disease tend to live significantly longer after disease onset and with milder cognitive decline than African-Americans and non-Hispanic whites, a study reports. The study, “Ethnoracial differences in Alzheimer’s disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort,” was published in the journal Alzheimer’s & Dementia.
Sterubin, an active chemical compound extracted from a native California plant, was found to hold neuroprotective and anti-inflammatory potential for Alzheimer’s disease, a study shows. The study, “Old age-associated phenotypic screening for Alzheimer’s disease drug candidates identifies sterubin as a potent neuroprotective…
A Phase 1 clinical trial in healthy volunteers for investigational therapy AZP2006 — an oral medicine that is meant to clear accumulations of toxic proteins in Alzheimer’s disease and progressive supranuclear palsy — has shown positive results, says the therapy’s developer, AlzProtect. Progressive supranuclear palsy (PSP) is a rare, progressive disease…
Denali Therapeutics has begun dosing patients in its Phase 1b clinical trial of DNL747 as a treatment for Alzheimer’s disease. “We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS [central nervous system] penetration, and target engagement, at the studied doses,”…
Get regular updates to your inbox.